Tirzepatide (Mounjaro): Benefits in Sueño Apnea and Cardiovascular Risks

Detailed report, written in Spanish, about Tirzepatida (commercialized mainly under the name Mounjaro) and its recent clinical trials related to Obstructive Apnea of the Sueño (AOS) and cardiovascular health.

Tirzepatide (Mounjaro): More about Diabetes and Obesity

Tirzepatide represents the new generation of drugs for the treatment of metabolic diseases. Unlike semaglutide (Ozempic/Wegovy), which imitates a single hormone (GLP-1), tirzepatide is the first dual agonist: it acts on the GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide) receptors. This double action boosts weight loss and glucose control in an unprecedented way.

Recently, large-scale clinical studies have demonstrated that its benefits extend beyond the scale, attacking serious comorbidities: pulmonary apnea and cardiovascular risk.

Benefits in Obstructive Sueño Apnea (AOS)

Obstructive Apnea of the Sueño is a serious disorder where breathing stops and restarts repeatedly during the sweat. In Spain, it is estimated that it affects millions of people, being closely linked to obesity (excess of soft tissue in the body collapses the respiratory tract).

The results come mainly from SURMOUNT-OSA clinical trials, published in 2024.

Drastic Reduction of the Apnea-Hypopnea Index (AHI)

The IAH measures how many times per hour breathing stops or becomes shallow.

Results: Patients treated with tirzepatide achieved an average reduction of up to 30 fewer events per hour (a small reduction in 60% at the beginning).

Clinical Impact: A significant number of participants achieved what is considered “remission” of the illness, reducing their apnea levels to levels where, technically, they could not require mechanical treatment.

Possible Independence from CPAP

The CPAP machine (that mask that inflates air to keep the road open) is the standard treatment (“Gold Standard”), but it has a low adherence rate because it is uncomfortable.

The study suggested that, thanks to the massive weight loss induced by the drug, many patients could no longer depend on CPAP or reduce the pressure required by the machine, substantially improving their quality of life and night rest.

Improved hypoxia and daytime fatigue

By reducing obstructions, it improves oxygen saturation in blood during the night. This translates into a reduction in excessive daytime sleepiness, a key factor in traffic and labor accidents.

Benefits in Riesgo Cardiovascular

Obesity is a “major” risk factor for the heart. By attacking visceral fat, tirzepatide generates a cascade of cardiovascular benefits that are more aesthetically pleasing.

Heart Failure with Preserved Eye Fraction (IC-FEP)

Recently, the SUMMIT essay shed light on this aspect. The IC-FEP is a condition where the heart pumps well, but is rigid and does not fill properly, very common among people with obesity.

Hallazgo: La tirzepatide reduces the risk of worsening heart failure and cardiovascular death.

Functional Capacity: Patients improved their ability to perform physical exercise without fatigue, something vital for this patient profile.

Arterial Pressure Control

Hypertension is the “silent ache” in Spain.

Studies show significant reductions in systolic (high) blood pressure in patients treated with tirzepatide. It is believed that this is due to both weight loss and a direct natriuretic (sodium elimination) effect of the drug.

Lipid Profile and Inflammatory Markers

Cholesterol: If a drastic reduction in triglycerides and non-HDL cholesterol (the “bad” and other atherogenic ones) has been observed, while HDL increases.

Inflammation: Reduce levels of C-Reactive Protein (CRP), a marker of systemic inflammation. Chronic inflammation is what damages blood vessels and causes heart attacks or strokes.

Mechanism: Why does it work so well?

The key is in the GIP + GLP-1 synergy:

Reduction of Visceral Fat: Weight is lost on the ground, fat is lost around the organs and the body. By eliminating grease from the pharyngeal zone, the airway is cleared mechanically (improving apnea).
Metabolic Improvement: By improving insulin sensitivity and reducing inflammation, stress on the heart and arteries decreases drastically. The heart has to work less to pump blood to a body with less mass and less vascular resistance.

Situation in Spain (Regulatory and Access Context)

It is important to land this information in the reality of the National Health System (SNS) and Spanish pharmacies:

Approval: Tirzepatide (Mounjaro) is approved in Spain by the AEMPS and the European Medicines Agency (EMA).

Indications:

Initially approved for Type 2 Diabetes.

Approved for Weight Control (Obesity or overweight with comorbidities).

Note: The specific indications for Apnea del Sueño or Cardiac Failure may later arrive at the official technical sheet, although doctors can prescribe it based on evidence (off-label or compassionate use in some cases, even for obesity and indirectly covers these pathologies).

Financing:

Currently, the NHS can finance these drugs only for Type 2 Diabetes under certain conditions (high BMI, failure of other drugs).

For the exclusive use of weight loss (and therefore improvement in apnea or CV risk without diabetes), the patient may have to pay for treatment out of pocket (private market), which involves a considerable monthly outlay.

Supply: Just like Ozempic, Spain has suffered intermittent stock problems due to extremely high global demand.

Medical Conclusion

Tyrzepatide is redefining the treatment of obesity. It is not seen as a drug “to lose weight”, but as a powerful therapeutic tool to treat cardiovascular and respiratory diseases with a metabolic basis.

For a patient in Spain with obesity and severe snoring (a bout of apnea) or hypertension, this drug offers a double solution: it attacks the root cause (excess adiposity) and directly improves survival and quality of life.

Doctor G Medical Excellence: Health, Bienestar and Longevidad

4243 W Hillsboro blvd Coconut Creek, 33073, FL

Phone: +1 (954) 638-1515